CN Patent

CN114957381B — 新型氘代氰基类化合物、其制备方法、组合物及应用

Assigned to Guangzhou Anovent Pharmaceutical Co Ltd · Expires 2026-04-17 · 0y expired

What this patent protects

本发明公开了一种如式I所示的新型氘代氰基类化合物，或其药学上可接受的盐、异构体或前药。还公开了上述氘代化合物的制备方法、组合物及应用。该类化合物作为3CL蛋白酶抑制剂，在病毒抑制活性相当的基础上，实现了更优的药动学性质和治疗效果，成药性更好，式I如下所示：

USPTO Abstract

本发明公开了一种如式I所示的新型氘代氰基类化合物，或其药学上可接受的盐、异构体或前药。还公开了上述氘代化合物的制备方法、组合物及应用。该类化合物作为3CL蛋白酶抑制剂，在病毒抑制活性相当的基础上，实现了更优的药动学性质和治疗效果，成药性更好，式I如下所示：

Drugs covered by this patent

Patent Metadata

Patent number
CN114957381B
Jurisdiction
CN
Classification
—
Expires
2026-04-17
Drug substance claim
No
Drug product claim
No
Assignee
Guangzhou Anovent Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.